Mabwell (Shanghai) Bioscience Co., Ltd.
Equities
688062
CNE100005RD2
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33.62 CNY | -2.21% | -3.67% | +2.84% |
May. 07 | Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821 | CI |
Apr. 29 | Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.84% | 1.86B | |
+7.52% | 113B | |
+11.38% | 106B | |
+0.96% | 22.27B | |
-12.64% | 22.22B | |
-5.20% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- 688062 Stock
- News Mabwell (Shanghai) Bioscience Co., Ltd.
- Mabwell Shanghai Bioscience Gets Nod to Trial Urothelial Cancer Drug